E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

• ClinicalTrials.gov Identifier: NCT01133977
• Recruitment Status: Completed
• First Posted: May 31, 2010
• Results First Posted: October 10, 2016
• Last Update Posted: October 10, 2016
• Sponsor: Eisai Inc.
• Collaborator: Quintiles, Inc.
• Information provided by (Responsible Party): Eisai Inc.

Study Description

Brief Summary:

Primary:

• Phase Ib: To define the safety, tolerability and maximum tolerated dose (MTD) of lenvatinib administered in combination with dacarbazine.
• Phase II: To evaluate the safety and tolerability of lenvatinib administered in combination with dacarbazine, compared with dacarbazine alone.

Secondary:

-Phase II: To make a preliminary assessment of the efficacy of lenvatinib administered in combination with dacarbazine, compared with dacarbazine alone.

Condition or disease	Intervention/treatment	Phase
Stage IV Melanoma	Drug: Lenvatinib; Drug: Dacarbazine	Phase 1; Phase 2

Detailed Description:

Safety was assessed by monitoring and recording all treatment emergent adverse events (AEs) and serious adverse events (SAEs); regular monitoring of clinical laboratory parameters; periodic measurement of vital signs and electrocardiograms (ECGs); dose limiting toxicities; performance of physical examinations; concomitant medications and procedures.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 97 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma.
• Study Start Date: April 2010
• Actual Primary Completion Date: June 2014
• Actual Study Completion Date: November 2014

Arms and Interventions

Arm	Intervention/treatment
Experimental: Lenvatinib + Dacarbazine (Phase 1b); Participants received 16 mg, 20 mg or 22 mg lenvatinib once daily in combination with dacarbazine	Drug: Lenvatinib; Lenvatinib tablets administered orally at doses of 16 mg, 20 mg, or 22 mg, once daily continuously over 3 weeks (21 days) during each 21-day cycle; Other Name: E7080; Drug: Dacarbazine; Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.; Other Name: Dacarbazine (DTIC)-Dome
Experimental: Lenvatinib + Dacarbazine (Phase 2); Participants received lenvatinib per the maximum tolerated dose (MTD) as determined in the Phase Ib of the study in combination with dacarbazine	Drug: Lenvatinib; Lenvatinib 20 mg (MTD/recommended Phase 2 dose as determined in Phase 1b of the study) administered once daily continuously over 3 weeks (21 days) during each 21-day cycle; Other Name: E7080; Drug: Dacarbazine; Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.; Other Name: Dacarbazine (DTIC)-Dome
Active Comparator: Dacarbazine (Phase 2); Participants received dacarbazine	Drug: Dacarbazine; Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.; Other Name: Dacarbazine (DTIC)-Dome

Outcome Measures

Primary Outcome Measures :

1. Dose Limiting Toxicity (DLT) of Lenvatinib Administered in Combination With Dacarbazine (for Phase 1b) [ Time Frame: From Day 1 through 21 days (one cycle) ]
   DLTs were defined as clinically significant adverse events (AEs) occurring less than or equal to 21 days after commencing study treatment and considered by the Investigator to be possibly or probably related to study treatment.
2. Number of Participants With Adverse Events/Serious Adverse Events (AEs/SAEs) [ Time Frame: From signing of informed consent up to 30 days after the last dose, up to approximately 2 years ]
   Safety assessments consisted of monitoring and recording all AEs, including all Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v. 4.0) grades, and SAEs; regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs and electrocardiograms (ECGs); and performance of physical examinations. Details of AEs and SAEs are provided in the reported adverse event section.

Secondary Outcome Measures :

1. Progression Free Survival (PFS) (for Phase 2) [ Time Frame: From the date of randomization until the date of disease progression or death (whichever was earlier) or up to approximately 2 years ]
   PFS was defined as the time from the date of randomization of a participant until (1) the date of first documented progression of such participant's disease based on Investigator assessments according to Response Evaluation Criteria In Solid Tumors (RECIST v. 1.1) or (2) the date of such participant's death due to any cause. Progression was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions, based on Investigator assessment according to RECIST 1.1. If missing assessments, imputed dates were used in the analysis.

Other Outcome Measures:

1. Time to Progression (TTP) (for Phase 2) [ Time Frame: From the date of randomization until disease progression or death or up to approximately 2 years ]
   TTP, defined as the time from the date of randomization until the date of progressive disease.
2. Overall Survival (OS) (for Phase 2) [ Time Frame: From the date of randomization until death or up to approximately 2 years ]
   OS, defined as the time from the date of randomization until the date of death. Few events of deaths (9 events in the Lenvatinib + Dacarbazine arm and 4 events in the Dacarbazine arm) were reported to calculate the median OS or to draw conclusions regarding the OS.
3. Overall Response Rate (ORR) (for Phase 2) [ Time Frame: From the date of randomization until disease progression or death or up to approximately 2 years ]
   ORR, defined as percentage of participants with best confirmed response (complete response [CR] or partial response [PR]). A confirmatory scan was required after no less than 4 weeks and no later than 8 weeks, starting on the date that the response was first recorded.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Patients with histologically-confirmed metastatic melanoma (Stage IV, American Joint Committee on Cancer (AJCC)).
2. No prior cytokine, chemotherapy, or targeted therapy for Stage IV melanoma.
3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
4. Life expectancy greater than or equal to 3 months.
5. At least 1 site of measurable disease by RECIST 1.1.
6. Adequate hematologic, renal, liver, and coagulation system function as defined by laboratory values performed within 21 days prior to initiation of dosing.
7. Blood pressure must be well-controlled (less than or equal to 140/90 mmHg at screening) with or without antihypertensive medication. Patients must have no history of hypertensive crisis or hypertensive encephalopathy.

Exclusion Criteria:

1. Known central nervous system (CNS) lesions, except for asymptomatic, nonprogressive, treated brain metastases. Treatment for brain metastases must have been completed at least 4 weeks prior to Day 1 and may include whole brain radiotherapy (WBRT), radiosurgery [RS; Gamma Knife, linear accelerator (LINAC), or equivalent] or a combination as deemed appropriate by the treating physician. Dexamethasone must be discontinued at least 3 weeks prior to Day 1. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to Day 1 will be excluded.
2. Lactate dehydrogenase greater than or equal to 2.0 x upper limit of normal (ULN).
3. Subjects with proteinuria greater than 1+ on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria. Subjects with 24-hour urine protein greater than or equal to 1 g/24 hours will be ineligible.
4. Pregnant, breast-feeding, or refusing double barrier contraception, oral contraceptives or avoidance of pregnancy measures.
5. Other active malignancy.
6. History of or known carcinomatous meningitis.
7. History of or known ocular melanoma.
8. Are currently receiving any other treatment for the tumor (including palliative radiotherapy) aside from control of symptoms.
9. Received treatment in another clinical study within the 30 days prior to commencing study treatment or patients who have not recovered from side effects of an investigational drug to grade less than or equal to 1, except for alopecia.
10. Received radiotherapy within the 30 days prior to commencing study treatment or have not recovered from side effects of all radiation-related toxicities to grade less than or equal to 1, except for alopecia.
11. Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical procedure, open biopsy, or significant traumatic injury within the 28 days prior to commencing study treatment. Minor surgery such as Portacath placement or skin biopsy is permitted if greater than or equal to 7 days have passed.
12. History of bleeding diathesis or coagulopathy.
13. Current use of anti-coagulants such as Vitamin K antagonists, unfractionated heparin, or low molecular weight heparin.

Contacts and Locations

Locations

United States, Maryland

Hagerstown, Maryland, United States

United States, New York

Albany, New York, United States

United States, South Carolina

Greenville, South Carolina, United States

United States, Texas

Dallas, Texas, United States

United States, Virginia

Norfolk, Virginia, United States

Germany

Berlin, Germany, 10249

Berlin, Germany, 12351

Berlin, Germany, 13585

Heidelberg, Germany, 69120

Muenchen, Germany, 81675

Italy

Bari, Italy, 70126

Milan, Italy, 20133

Milian, Italy, 20141

Napoli, Italy, 80131

Siena, Italy, 53100

Spain

Barcelona, Spain

Madrid, Spain, 28033

Madrid, Spain, 28034

Madrid, Spain, 28050

Valenica, Spain, 46014

United Kingdom

Dorset, United Kingdom

Glasgow, United Kingdom

Manchester, United Kingdom

Middlesex, United Kingdom

Oxford, United Kingdom

Southampton, United Kingdom

Wirral, United Kingdom

Sponsors and Collaborators

Eisai Inc.

Quintiles, Inc.

Investigators

• Study Director: Dave Harish; Quintiles, Inc.

More Information

• Responsible Party: Eisai Inc.
• ClinicalTrials.gov Identifier: NCT01133977
• Other Study ID Numbers: E7080-702
• First Posted: May 31, 2010
• Results First Posted: October 10, 2016
• Last Update Posted: October 10, 2016
• Last Verified: August 2016

Additional relevant MeSH terms:

Melanoma; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Lenvatinib; Dacarbazine; Antineoplastic Agents; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents, Alkylating; Alkylating Agents